| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
103,127 |
77,063 |
$19.90M |
| G0467 |
Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
6,712 |
4,973 |
$1.03M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
29,176 |
24,182 |
$1K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
9,211 |
8,010 |
$75.00 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
6,153 |
5,411 |
$18.10 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
173 |
167 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,637 |
1,622 |
$0.00 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
394 |
394 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,028 |
963 |
$0.00 |
| J1817 |
Insulin for administration through dme (i.e., insulin pump) per 50 units |
57 |
55 |
$0.00 |
| Z7610 |
|
2,099 |
1,429 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
19 |
19 |
$0.00 |
| 99443 |
|
919 |
898 |
$0.00 |
| 90686 |
|
665 |
665 |
$0.00 |
| 90371 |
|
42 |
42 |
$0.00 |
| G2025 |
Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only |
73 |
67 |
$0.00 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
229 |
197 |
$0.00 |
| 99441 |
|
4,318 |
4,036 |
$0.00 |
| 99422 |
|
363 |
348 |
$0.00 |
| A6441 |
Padding bandage, non-elastic, non-woven/non-knitted, width greater than or equal to three inches and less than five inches, per yard |
293 |
148 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
102 |
95 |
$0.00 |
| 90732 |
|
188 |
188 |
$0.00 |
| 85018 |
|
899 |
863 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,169 |
1,090 |
$0.00 |
| 90733 |
|
46 |
46 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
46 |
43 |
$0.00 |
| 99243 |
|
15 |
15 |
$0.00 |
| 0011A |
|
27 |
27 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
72 |
69 |
$0.00 |
| 81003 |
|
3,876 |
3,521 |
$0.00 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,421 |
1,421 |
$0.00 |
| 99201 |
|
69 |
69 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,169 |
1,090 |
$0.00 |
| 81025 |
|
1,064 |
1,043 |
$0.00 |
| 99442 |
|
3,211 |
3,048 |
$0.00 |
| A6021 |
Collagen dressing, sterile, size 16 sq. in. or less, each |
233 |
119 |
$0.00 |
| 99215 |
Prolong outpt/office vis |
2,512 |
2,364 |
$0.00 |
| 82948 |
|
770 |
712 |
$0.00 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
186 |
185 |
$0.00 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,596 |
1,590 |
$0.00 |
| 90658 |
|
169 |
169 |
$0.00 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
119 |
119 |
$0.00 |
| 90715 |
|
304 |
303 |
$0.00 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
341 |
321 |
$0.00 |
| 86318 |
|
359 |
356 |
$0.00 |
| 90649 |
|
43 |
43 |
$0.00 |
| Z6500 |
|
12 |
12 |
$0.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
70 |
70 |
$0.00 |
| 69209 |
|
28 |
26 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
14 |
14 |
$0.00 |
| 99423 |
|
31 |
31 |
$0.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
25 |
25 |
$0.00 |